openPR Logo
Press release

Investigation for Long-Term Investors in shares of Volkswagen AG (OTC: VWAGY / OTC: VLKAF / OTC: VWAPY) announced

05-27-2020 11:48 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Volkswagen AG (OTC: VWAGY / OTC: VLKAF / OTC: VWAPY) shares over potential wrongdoing.

An investigation on behalf of investors in Volkswagen AG (OTC: VWAGY / OTC: VLKAF / OTC: VWAPY) shares over potential wrongdoing.

An investigation on behalf of current long-term investors in shares of Volkswagen AG (OTC: VWAGY / OTC: VLKAF / OTC: VWAPY) was announced over potential breaches of fiduciary duties by certain officers and directors at Volkswagen AG.

Investors who purchased shares of Volkswagen AG (OTC: VWAGY / OTC: VLKAF / OTC: VWAPY) and currently hold any of those Volkswagen AG shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Volkswagen AG (directors breached their fiduciary duties and caused damage to the company and its shareholders.

On September 25, 2015, a lawsuit was filed against Volkswagen AG (alleged securities laws violations. The plaintiff claimed that the defendants misled investors by failing to disclose that the Company had utilized a "defeat device" in certain of its diesel cars that allowed such cars to temporarily reduce emissions during testing, while achieving higher performance and fuel economy, as well as discharging dramatically higher emissions, when testing was not being conducted. The use of this device allowed Volkswagen to market its diesel vehicles to environmentally conscious consumers, increasing its sale of diesel cars in the United States and abroad and, as a result, its profitability. As a result of defendants' scheme and false and misleading statements and omissions, Volkswagen's ordinary and preferred ADRs traded at artificially inflated prices, reaching highs of $54.82 and $56.55 per ADR, respectively, on December 30, 2013.

The Company pled guilty to criminal charges, paid a $2.8 billion criminal fine, a $2.7 billion fine for environmental mitigation, another $2 billion for clean-emissions infrastructure, while total costs associated to rectifying the emissions issue have exceeded $18 billion.

Those who purchased shares of Volkswagen AG (OTC: VWAGY) (OTC: VLKAF) (OTC: VWAPY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation for Long-Term Investors in shares of Volkswagen AG (OTC: VWAGY / OTC: VLKAF / OTC: VWAPY) announced here

News-ID: 2059969 • Views: 1014

More Releases from Shareholders Foundation

Investigation announced for Investors in shares of Laboratory Corporation of Ame …
An investigation was announced concerning potential securities laws violations by Laboratory Corporation of America Holdings in connection with certain financial statements. Investors who purchased shares of Laboratory Corporation of America Holdings (NYSE: LH), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Laboratory Corporation of America Holdings regarding its business,
Investigation announced for Investors in Aytu BioScience, Inc. (NASDAQ: AYTU)
An investigation on behalf of investors of Aytu BioScience, Inc. (NASDAQ: AYTU) shares over potential securities laws violations by Aytu BioScience, Inc. (NASDAQ: AYTU and certain of its directors and officers in connection with certain financial statements was announced. Investors who purchased shares of Aytu BioScience, Inc. (NASDAQ: AYTU), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm
DraftKings Inc. (NASDAQ: DKNG) Investor Alert: Update in Lawsuit
The Shareholders Foundation announced an update in the lawsuit that is pending for certain investors in shares of DraftKings Inc. (NASDAQ: DKNG). If you purchased shares of DraftKings Inc. (NASDAQ: DKNG) prior to December 2019 and continue to hold any of those shares, you have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On July 2, 2021, a lawsuit was filed
Lawsuit filed for Investors in shares of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP …
An investor, who purchased shares of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), filed a lawsuit over alleged violations of Federal Securities Laws by NRx Pharmaceuticals, Inc. Investors who purchased shares of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) have certain options and for certain investors are short and strict deadlines running. Deadline: March 21, 2022. NASDAQ: NRXP investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Wilmington, DE based NRX

All 5 Releases


More Releases for OTC:

OTC: VWAGY / OTC: VLKAF / OTC: VWAPY Shareholder Notice: Update in Lawsuit again …
The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Volkswagen AG (OTC: VWAGY) (OTC: VWAPY) shares. Investors, who purchased shares of Volkswagen AG (OTC: VWAGY) (OTC: VLKAF) (OTC: VWAPY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On September 25, 2015, a lawsuit was filed against Volkswagen AG (alleged securities laws violations. The plaintiff claimed that the defendants
Foods Matrix Inc. Exploring OTC Markets Listing
Foods Matrix Inc. (FMI), a US based food processing startup is exploring options to list on the OTC Markets. FMI is in talks to acquire a distressed food processing unit in the state of Punjab, India for US $3 million. The deal may be sealed by the end of November, 2018, post completion of the ongoing due diligence. FMI may initially quote on the pink sheet segment of the OTC Markets
03-14-2018 | Health & Medicine
Fact.MR
OTC Analgesics Market Report 2017-22: Pharmacy to Remain the Most Lucrative OTC …
A fresh study, covering “OTC Analgesics Market Forecast, Trend Analysis & Competition Tracking – Global Review 2017 to 2022” has been broadcasted to wide online repository of Fact MR, which presents deep focus on the healthcare market. This smart study contains precise data that offers a clear insight about market current scenario and future projections for the benefit of readers. Moreover, the study enclosed significant data which tends to make
11-28-2017 | Health & Medicine
Fact.MR
7 Key Projections for OTC Analgesics Market
The global OTC analgesics market is projected to register an above-average CAGR during 2017 to 2022. Global sales of OTC analgesics is estimated to account for nearly US$ 25,000 Mn revenues by 2022-end. Request For Sample Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=75 The trend of using off-label drugs that are affordable and unapproved, but effective in treating diseases, has been witnessing an upsurge over the past few years. Various off-label drugs including tricyclic antidepressants, antihistamines,
OTC Drug Market Report Research : 2017
Reports And Markets Publish a New Market Research Report On –" OTC Drug Market Report Research : 2017" Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/asia-pacific-otc-drug-market-report-2017-1541262 In this report, the Asia-Pacific OTC Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several
OTC Perspectives Announces 2010 Ad Awards Finalists
FLORHAM PARK, N.J. [March 22, 2010] – OTC Perspectives, Inc., the leading conference, training and publishing company for over-the-counter (OTC) marketing, today announced the finalists for the 2nd annual OTC National Advertising Awards, presented in conjunction with the OTC National Conference, May 18-19, in Philadelphia, PA. The award winners will be announced at the OTC National Advertising Awards reception, sponsored by HealthCentral, on the night of May l8,